לאקומייד 100 מג ישראל - עברית - Ministry of Health

לאקומייד 100 מג

cts chemical industries ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 100 mg - lacosamide

לאקומייד 150 מג ישראל - עברית - Ministry of Health

לאקומייד 150 מג

cts chemical industries ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 150 mg - lacosamide

לאקומייד 200 מג ישראל - עברית - Ministry of Health

לאקומייד 200 מג

cts chemical industries ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 200 mg - lacosamide

לאקומייד 50 מג ישראל - עברית - Ministry of Health

לאקומייד 50 מג

cts chemical industries ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 50 mg - lacosamide

טרנדייט טבליות 100 מג ישראל - עברית - Ministry of Health

טרנדייט טבליות 100 מג

padagis israel agencies ltd, israel - labetalol hydrochloride - טבליה - labetalol hydrochloride 100 mg - labetalol - labetalol - treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.

פלומיסט קואדריוואלנט ישראל - עברית - Ministry of Health

פלומיסט קואדריוואלנט

astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.

טסיגנה 200 מג ישראל - עברית - Ministry of Health

טסיגנה 200 מג

novartis israel ltd - nilotinib as monohydrate - קפסולות - nilotinib as monohydrate 200 mg - nilotinib - nilotinib - treatment of philadelphia chromosome positive chronic myeloid leukaemia (ph+ cml) in chronic or accelerated phase in patients resistant to or experiencing significant toxicity during treatment with imatinib.treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

טסיגנה 150 מג ישראל - עברית - Ministry of Health

טסיגנה 150 מג

novartis israel ltd - nilotinib as hydrochloride monohydrate - קפסולות - nilotinib as hydrochloride monohydrate 150 mg - nilotinib - nilotinib - treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

לוותרים 250 ישראל - עברית - Ministry of Health

לוותרים 250

trima israel pharmaceutical products maabarot ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 250 mg - levetiracetam - levetiracetam - - levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetrim is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - levetrim is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - levetrim is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

לוותרים 500 ישראל - עברית - Ministry of Health

לוותרים 500

trima israel pharmaceutical products maabarot ltd - levetiracetam - טבליות מצופות פילם - levetiracetam 500 mg - levetiracetam - levetiracetam - - levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetrim is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - levetrim is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - levetrim is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.